EmphyCorp Inc has completed 19 Human FDA Clinical Studies with thousands of Patients that demonstrated the safety and efficacy of Inhaled N115 Nasal Spray and Oral Delivery (Sodium Pyruvate, a natural human anti-inflammatory agent) with no known side effects

Reducing the number of cases, symptoms, and severity of seasonal flu respiratory tract infections and for COVID-19.

The 19 Human Clinical Studies was a multi-year, nine arm study that included Patients with Covid-19 infections, Long COVID, COPD, Pulmonary Fibrosis, Cystic Fibrosis, Allergic Rhinitis, Chronic Rhinitis, Sinusitis, and Flu.

N115 significantly reduced nasal and respiratory inflammation, inflammatory cytokines, reduced hypoxemia and shortness of breath, and significantly increased lung functions in all patients treated with N115.

We have treated over 3.5 million Patients globally in 200 hospitals, with no adverse events. Our results were accepted in the peer reviewed, prestigious European Journal of Respiratory Medicine.

In a Phase III Clinical Trial in active COVID-19 infected patients, N115 Nasal Spray reduced viral numbers under 9,000 by day 6.4 vs 10.3 days for untreated patients, and was significantly effective in reducing, coughing/sneezing, fatigue, and preventing the spread of COVID-19.

In a Phase III Clinical Trial with COVID-19 Long Haulers (long COVID), N115 Nasal Spray clinically and significantly reduced coughing/sneezing, reduced headaches and body aches, increased Sa02 levels, and improved breathing.

In a Phase III Clinical Trial, patients with Pulmonary Fibrosis, there was a statistically and clinically significant improvement in all lung functions, with the use of N115 Nasal Spray compared to baseline, including an increase in FEV-1, SaO2, FVC, FEV-1/FVC ratios (from 52% to 86%) and a decrease in hypoxemia, along with a reduction in coughing and fatigue.

Find out More
Animation of covid 19 cells and medical worker in ppe suit. global covid 19 pandemic concept digitally generated video.

Investor Relations

EmphyCorp Inc. is a Private Biotech in Flemington, New Jersey that specializes in Nasal Sprays for Respiratory, COVID-19, COVID-19 Long COVID, Flu and more.

Drug Pipeline

We are driven with a passion for creating Non-Steroidal Nasal Spray Drugs with no adverse effects for chronic breathing diseases, COVID-19, Long COVID, and Flu that help Patients with symptoms relief and improves their quality of life.

New Products and Research

Please see our Drug Pipeline for Details.

Emphycorp Inc in the News

For the latest news on our research and development of new products, reviews and more.

Find out More
emphycorp inc no steroidal nasal spays


EmphyCorp is a Private NJ Biotech focused on Providing Safer Rx Nasal Spray Drugs with no known side effects for the treatment of major Respiratory Diseases and COVID-19, including Pulmonary Fibrosis, Cystic Fibrosis, COPD, Flu, COVID-19, and COVID Long Haulers Treatments.

Three Successful Phase III N115 Nasal Spray Clinical Trials were completed for Pulmonary Fibrosis, COVID-19, and COVID-19 Long Haulers (Long COVID) Treatments.

A Phase III Clinical Trial for Flu will start soon.

In 2021, a new Hypoxemia Drug Patent (7th Patent) was granted, while three additional Drug Patents are Pending.

Our Drug Patents total 70+ worldwide, including China.

N115 Non-Steroidal Nasal Spray with no known side effects increases Nasal Nitric Oxide that is beneficial to many Patients that have Hypoxemia symptoms (Low Oxygen, Shortness of Breath, Coughing, Headaches), even though they are taking existing approved drugs for Pulmonary Fibrosis, Cystic Fibrosis, COPD, Asthma, Heart Medications (like Entresto®), and more.

Investment is an asset or item that is purchased that it will generate income or appreciate in the future.
J.P. Morgan — Senior Partner & CEO
Investor Relations